The ROCK inhibitor eye drop accelerates corneal endothelium wound healing.

PURPOSE To evaluate the effect of Rho kinase (ROCK)-inhibitor eye drops on a corneal endothelial dysfunction primate model and human clinical case series of corneal endothelial dysfunction. METHODS As a corneal-endothelial partially injured model, the corneal endothelium of seven cynomolgus monkeys was damaged by transcorneal freezing; 10 mm of rock inhibitor Y-27632 was then applied topically 6 times daily. The phenotype of the reconstructed corneal endothelium was evaluated by immunohistochemical analysis and noncontact specular microscopy. For clinical study, the effect of Y-27632 eye drops after transcorneal freezing was evaluated in eight corneal endothelial dysfunction patients: four central corneal edema patients and four diffuse corneal edema patients. RESULTS Slit-lamp microscopy revealed that both Y-27632-treated and -nontreated corneas became hazy after transcorneal freezing, and then recovered their transparency within 4 weeks. ROCK inhibitor Y-27632 promoted recovery of corneal endothelial cell density and wound healing in terms of both morphology and function. The percentage of ZO-1 and Na(+)/K(+)-ATPase positive cells in the regenerated area in the Y-27632 group was significantly higher than in the controls. Noncontact specular microscopy revealed that corneal endothelial cell density was significantly higher in the Y-27632 group compared with the controls at 4 weeks; cell density reached approximately 3000 cells/mm(2), as opposed to 1500 cells/mm(2) in the control group. In addition to the animal study findings, the clinical study findings showed that Y-27632 eye drops effectively improved corneal edema of corneal endothelial dysfunction patients with central edema. CONCLUSIONS These findings show that rock inhibitor Y-27632 eye drops promote corneal endothelial wound healing in a primate animal model and suggest the possibility of Y-27632 as a novel therapeutic modality for certain forms of corneal endothelial dysfunction. (http://www.umin.ac.jp/ctr/ number, UMIN000003625.).

[1]  N. Koizumi,et al.  Rho-Associated Kinase Inhibitor Eye Drop Treatment as a Possible Medical Treatment for Fuchs Corneal Dystrophy , 2013, Cornea.

[2]  N. Koizumi,et al.  ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. , 2012, The American journal of pathology.

[3]  D. Tan,et al.  Endothelial keratoplasty: a revolution in evolution. , 2012, Survey of ophthalmology.

[4]  N. Koizumi,et al.  Development of new therapeutic modalities for corneal endothelial disease focused on the proliferation of corneal endothelial cells using animal models. , 2012, Experimental eye research.

[5]  N. Koizumi,et al.  The New Therapeutic Concept of Using a Rho Kinase Inhibitor for the Treatment of Corneal Endothelial Dysfunction , 2011, Cornea.

[6]  N. Koizumi,et al.  Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops , 2011, British Journal of Ophthalmology.

[7]  G. Melles,et al.  Spontaneous corneal clearance despite graft detachment in descemet membrane endothelial keratoplasty. , 2009, American journal of ophthalmology.

[8]  N. Koizumi,et al.  Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. , 2009, Investigative ophthalmology & visual science.

[9]  Noriko Koizumi,et al.  Cultivated Corneal Endothelial Transplantation in a Primate: Possible Future Clinical Application in Corneal Endothelial Regenerative Medicine , 2008, Cornea.

[10]  Noriko Koizumi,et al.  Cultivated corneal endothelial cell sheet transplantation in a primate model. , 2007, Investigative ophthalmology & visual science.

[11]  M. Inatani,et al.  Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. , 2007, Investigative ophthalmology & visual science.

[12]  J. Liao,et al.  Rho Kinase (ROCK) Inhibitors , 2007, Journal of cardiovascular pharmacology.

[13]  S. Nishikawa,et al.  A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.

[14]  W. Dai,et al.  TGF-β2 inhibits AKT activation and FGF-2-induced corneal endothelial cell proliferation , 2006 .

[15]  T. Okano,et al.  Functional human corneal endothelial cell sheets harvested from temperature‐responsive culture surfaces , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  M. Araie,et al.  Treatment of rabbit bullous keratopathy with precursors derived from cultured human corneal endothelium. , 2005, Investigative ophthalmology & visual science.

[17]  Robin Shattock,et al.  In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.

[18]  A. Bresnick,et al.  Cell Type-specific Regulation of RhoA Activity during Cytokinesis* , 2004, Journal of Biological Chemistry.

[19]  M. Araie,et al.  Cultured human corneal endothelial cell transplantation with a collagen sheet in a rabbit model. , 2004, Investigative ophthalmology & visual science.

[20]  Michael F. Olson,et al.  RAS and RHO GTPases in G1-phase cell-cycle regulation , 2004, Nature Reviews Molecular Cell Biology.

[21]  N. Fullwood,et al.  Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. , 2004, Investigative ophthalmology & visual science.

[22]  Anne J. Ridley,et al.  ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.

[23]  N. Joyce Proliferative capacity of the corneal endothelium , 2003, Progress in Retinal and Eye Research.

[24]  A. Hall,et al.  Rho GTPases and the actin cytoskeleton. , 1998, Science.

[25]  G. Vrensen,et al.  Corneal endothelium and growth factors. , 1996, Survey of ophthalmology.

[26]  A. Ashworth,et al.  An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1 , 1995, Science.

[27]  T. Sakai,et al.  ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. , 1993, Oncogene.

[28]  W. Treffers Human corneal endothelial wound repair. In vitro and in vivo. , 1982, Ophthalmology.

[29]  R. Hyndiuk,et al.  Endothelial wound repair in primate cornea. , 1975, Experimental eye research.

[30]  F. Price,et al.  Spontaneous corneal clearance despite graft detachment after descemet membrane endothelial keratoplasty. , 2010, American journal of ophthalmology.

[31]  T. Nakagami,et al.  Connexin43 knockdown accelerates wound healing but inhibits mesenchymal transition after corneal endothelial injury in vivo. , 2008, Investigative ophthalmology & visual science.

[32]  T. Tanishima,et al.  Wound-healing of corneal endothelium in monkey: an autoradiographic study. , 1983, Japanese journal of ophthalmology.

[33]  T. Tanishima,et al.  Wound-healing of the corneal endothelium in the monkey: a morphometric study. , 1982, Japanese journal of ophthalmology.